An observational study in Wound Infection, sponsored by MolecuLight Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by MolecuLight Inc. · Observational
Among 11 studies in Wound Infection with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Wound Infection · Canada.
Among the 11 studies in Wound Infection with a site in Canada, this one is the only one that started in 2022, is one of 2 observational ones, and was the 9th registered.
270 studies on the registry are indexed under Wound Infection; 33 are open to participants now.
Browse Wound Infection studies →2 of the 11 studies in Wound Infection with a site in Canada are open now. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University of Manitoba · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 23 Wound Infection studies recruiting now, 17 (74%) set no upper age limit and 1 (4%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2022.
This study's enrollment of 40 is below the median of 141 across 28 observational studies indexed under Wound Infection.
Median enrollment 150 across the 9 interventional studies, 58 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 9 most frequent:
MolecuLight Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
MolecuLight Inc. has 1 study filed under Wound Infection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Wound Infection with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-blind, controlled trial. There are two arms and 20 patients with acute or chronic wounds with clinical suspicion of biofilm (CSB+/CSB-) are allocated in each arm. The primary objective is to evaluate the diagnostic accuracy of MolecuLight fluorescence in identifying biofilm as validated by gold standard SEM imaging.
Male and female subjects presenting with acute or chronic wounds
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with negative clinical suspicion of Biofilm containing wounds(CSB-).
Device: MolecuLight DX Imaging Device
Patients with positive clinical suspicion of Biofilm containing wounds(CSB+)
Device: MolecuLight DX Imaging Device
The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
Diagnostic accuracy of fluorescence signature to predict presence or absence of wound biofilm measured by moderate/ heavy bacterial load
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in May 2022, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MolecuLight Inc.